Figure 2. Synthesis of Dihydroisoxazole Derivatives
See text for details. tion with 5 mM GSH at pH 7.2, no changes were detected in the concentration of 1b and the same result Prepared dihydroisoxazole compounds were assayed against recombinant human TG2 using an enzyme cou-was observed at pH 9.0. This finding (k < 1 min −1 M −1 ) suggests that the dihydroisoxazole warhead is likely to pled assay [14, 15], where glutamate dehydrogenase was used to couple ammonium ion, a product of the retain reasonable stability in physiological systems, even at a pH where some amount of the thiol is present TG2-catalyzed reaction, to α-ketoglutarate to yield glutamate and the simultaneous oxidation of NADH to in the thiolate form. Other dihydroisoxazole compounds tested showed NAD + was monitored at 340 nm to follow the reaction progress. All the tested compounds exhibited time-similar stabilities with 1b except compounds 3f and 4, which have a dioxobenzothiophene group. When incu-dependent inactivation of TG2 and kinetic parameters were obtained by plotting the reaction progress curve bated with 5 mM GSH at pH 7.2, the latter compounds decomposed almost completely within 10 min to multi-against theoretical equations of the irreversible inhibition model (Figure 3) [12].
Reactivity of Dihydroisoxazole Inhibitors toward Alternative Physiological Nucleophiles
ple products, which have not been characterized fully yet. No decomposition was observed in solutions with-The assay results showed that compounds 1a and 1b are also reasonably active against human TG2, al-out the thiol added. An analog of compound 3f, which has a tyrosine methyl ester group instead of the dihy-though their specificity (k inh /K I ) is significantly less than the reported values against bovine epidermal transglu-droisoxazole methyl amide, also decomposed quickly in the presence of GSH confirming that the dioxoben-taminase [11]. Several analogs were prepared to assess the structure-activity relationships of 1. Changing the zothiophene group is responsible for the instability. However, this control compound has insignificant TG2 bulky benzyloxycarbonyl (Cbz) group on the α-amino group to a small acetyl group (3a) decreased the inhibi-inhibition activity, suggesting that the TG2 inhibitory activities of 3f and 4 are not correlated with their reac-tion activity. Similar results were observed when the secondary amide group connecting the dihydroisoxa-tivity toward simple nucleophiles. zole ring to the rest of the molecule was replaced with an ester or a tertiary amide group in compounds 2a and Biology of Dihydroisoxazole Inhibitors Activity of 1b against Tumor Cell Lines in Culture 2b, respectively. Based on these results, the Cbz and amide groups were fixed and the side chain of the Studies with competitive TG2 substrate analogs have shown that inhibition of TG2 sensitizes certain tumor amino acid moiety was varied using different amino acids (1c-1i). The analog derived from tryptophan or cells to death induced by proapoptotic agents ([16], L.Y. et al., unpublished data). To demonstrate chemo-γ-substituted aspartic acid retained potent inhibition activity against TG2 while the alanine or D-phenylanine sensitization activity of the dihydroisoxazole inhibitors described in this report, a cell-based assay was devel-derivatives exhibited significantly reduced activity. The assay results for this series of compounds indicate that oped using HCT-116, a human colon cancer cell line, and epothilone C, a member of a promising class of the bulky side chain and its stereochemistry are important for the inhibitor activity. In another series of com-tubulin binding anticancer agents (see for example [17-19]). As shown in Figure 4 , incubation of HCT-116 with pounds (3b-3f) with different aryl carbamate groups, K I decreased at least 5-fold compared with 1b and dioxo-increasing levels of 1b in the 1-100 µM range reduced the GI 50 for epothilone C by >2-fold. When used by benzothiophenyl derivative 4 showed the most promising inhibition activity. itself, no cytotoxicity was observed for 1b at concentra- tions below 100 M. Similar findings have also been Our interest in pharmacologically useful TG2 inhibitors is especially motivated by their potential utility for observed (data not shown) using the U87 glioblastoma cell line and the clinically important cytotoxic agent treating Celiac Sprue, a widespread disorder of the small intestine for which no pharmacologic therapy is BCNU [20].
Pharmacokinetics, Pharmacodynamics, currently available (see for example [21-23]). For this application, an inhibitor with a short serum half-life is and Bioavailability of 1b in Mice
Preliminary experiments with mice showed that com-desirable so that the compound, when dosed orally, is primarily localized to the diseased organ (the small in-pound 1b has sufficient solubility, stability, and bioavailability for further in vivo studies. Collected serum testine). At the same time, the TG2 inhibitor must also have adequate bioavailability so that it can penetrate samples were extracted with ethyl acetate and the separated organic layer was analyzed using analytical into the intestinal lamina propria, the primary location of pathologically relevant TG2 [24]. To estimate the oral HPLC or LC-MS. Serum levels were calculated using a calibration curve. When injected intraperitoneally, the bioavailability of 1b, the compound was dosed orally in mice at 80 mg/kg. Blood samples were collected 30 concentration of 1b in serum samples collected 5 min after injection was 11 and 24 M for 20 and 40 mg/kg dosages, respectively. At the higher dose, the serum concentration dropped to 11 M after 10 min, and below the lower limit of quantitation (3 M) after 30 min. Together, these results demonstrate that compound 1b can maintain a pharmacologically useful concentration in serum in a dose-dependent manner, and that it has a relatively short half-life in serum. No metabolites could be reliably detected. with 50 M of analog 5 for 1 hr resulted in strong labeland bilirubin levels were not statistically different being of the cell plasma membrane, together with weaker tween the groups of mice treated with 1b or vehicle but distinct granular labeling of the cytosol ( Figure 6 ). only (ALP, 98 ± 42 versus 146 ± 9 U/l; bilirubin, 0.16 ± The former pattern presumably reflects the abundance 0.11 versus 0.13 ± 0.07 mg/dl), whereas the level of alaof TG2 anchored in the extracellular matrix of HCT-116 nine aminotransferase was elevated in the inhibitorcells, whereas granular intracellular staining may be retreated mice (360 ± 122 versus 79 ± 45 U/l). These related to its presence in secretory granules or to a posults suggest that mice can tolerate relatively high tential receptor-mediated endocytotic process. systemic doses of a dihydroisoxazole inhibitor such as 1b for at least 2 weeks. Elevated liver enzyme levels Discussion suggest that hepatic tissue is a potential primary site of the dose-limiting effects of compound 1b.
Human TG2 is a structurally and mechanistically com-Chemosensitization of Refractory Glioblastoma plex protein [28] with multiple biological functions [1-Tumors by 1b in Mice 3]. It is an especially interesting medicinal target, since Based on the good safety and in vitro efficacy of 1b, it plays a crucial role in the pathogenesis of several we were prompted to evaluate its ability to enhance the unrelated disorders, yet it appears to be nonessential sensitivity of chemotherapy against refractory tumors in mammals. Consequently, small molecule inhibitors of in animals. Balb/C mice were injected subcutaneously with 2 × 10 6 syngeneic DBT glioblastoma cells, and tuthis enzyme can be useful probes not just for TG2 biolmors were allowed to establish for 1 week [25-27]. Mice ogy but also its role in a variety of diseases. Here we were then treated with daily intraperitoneal injections with either vehicle or TG2 inhibitor starting on day 8 for 10 treatments. On day 10 and 12, mice were coinjected with vehicle or BCNU (10 mg/kg and 5 mg/kg, respectively). This dosage schedule of BCNU results in minimal effect on the DBT tumors in this experimental paradigm. Tumors were removed and weighed 3 weeks after start of the experiment, and the mean tumor weight was separately calculated for each cohort. The results, summarized in Figure 5 , demonstrate excellent dosedependent efficacy of 1b. 
Visualizing the Action of Dihydroisoxazole Inhibitors on Cells TG2 is found in various tissues and subcellular locations. To understand the biological and pathogenic roles of this ubiquitous enzyme, small molecule agents are needed to visualize its spatial distribution and tem-

have analyzed the structure-activity relationships of di-for hepatotoxicity based on elevation of serum transhydroisoxazole inhibitors of human TG2 and investiaminase levels without a significant effect on alkaline gated the properties of a lead compound in vitro and phosphatase or bilirubin. Further studies would be rein vivo. quired to assess whether this is an intrinsic property of A series of compounds with variations at three dif-
all TG2 inhibitors or whether it reflects non-mechanismferent positions have been prepared and tested to exassociated toxicity of 1b. amine the relationship between the molecular structure and the inhibition properties. Based on their inhibitory 
